natgillin/translations-raw huggingface dataset:
Very common: decreased appetite Uncommon: cachexia 
Redki: bolezen graft-versus-host * Presnovne in prehranske motnje Zelo pogosti: zmanjšan apetit Občasni: kaheksija
• Ringing in ears 
• zvonjenje v ušesih
In case of such combination, INR values should be monitored. 
Pri takšni kombinaciji je treba spremljati vrednosti INR.
Swallow the tablet with a full glass of water. 
Tableto pogoltnite s polnim kozarcem vode.
Dose adjustment is usually not required. 
Prilagoditev odmerjanja običajno ni potrebna.
Add supportive care as indicated. 
Uvedite podporno oskrbo, kot je indicirano.
Median age: 64 years. 
Mediana starost: 64 let.
Tell your doctor straight away if you notice any of the following side effects - you may need urgent medical treatment: 
Zdravniku takoj povejte, če opazite katerega od naslednjih neželenih učinkov - morda boste potrebovali nujno medicinsko pomoč:
Interrupt treatment. 
Prekinite zdravljenje.
When dose reduction is necessary, it is recommended to reduce to 40 mg daily, and then to 20 mg daily. 
Če je treba odmerek zmanjšati, se priporoča zmanjšanje na 40 mg na dan in nato na 20 mg na dan.
• Protein in urine (seen in tests) 
• beljakovine v urinu (razvidno iz preiskav)
One event was Grade 3; the remainder were Grade 2. 
En dogodek je bil 3. stopnje; ostali dogodki so bili 2. stopnje.
1 stratified log-rank test 
1 stratificirani test log-rank
As most events occur early in the course of treatment, the physician should evaluate the patient closely during the first eight weeks of treatment to determine if dose modifications are warranted. 
Ker se večina dogodkov pojavi zgodaj v teku zdravljenja, mora zdravnik bolnika v prvih osmih tednih zdravljenja skrbno spremljati, da oceni, ali je treba odmerek prilagoditi.
Perforations and fistulas 
Perforacije in fistule
Two dose reductions were required in 19.3% of patients. 
Dve zmanjšanji odmerka sta bili potrebni pri 19,3 % bolnikov.
Partial responses 
Delni odzivi
Not known (proportion of people affected not known) 
Neznana pogostnost (delež prizadetih bolnikov ni znan)
Frequencies are based on all grades and defined as: very common (≥1/10), common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); not known (cannot be estimated from the available data). 
Pogostnosti temeljijo na vseh stopnjah in so opredeljene kot: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100) in neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov).
The effects of CABOMETYX in people younger than 18 years old are not known. 
Učinki zdravila CABOMETYX pri ljudeh, mlajših od 18 let, niso znani.
This effect was not associated with a change in cardiac wave form morphology or new rhythms. 
Ta učinek ni povezan s spremembo morfologije oblike zobcev srca ali novimi ritmi.
Caucasian: 56%, Asian: 34% 
Belci: 56 %, Azijci: 34 %.
Male: 82% 
Moški spol: 82 %.
Partial Response Median time to First Response, months (95% CI) Stable Disease as Best Response Progressive Disease as Best Response 1 chi-squared test 
Delni odziv Mediani čas do prvega odziva, meseci (95-% IZ) Stabilna bolezen kot najboljši odziv Napredujoča bolezen kot najboljši odziv 1 test hi-kvadrat
4 stratified Cochran-Mantel-Haenszel (CMH) test 
4 stratificirani Cochran-Mantel-Haenszel-ov (CMH) test
Institute appropriate medical care. 
Uvedite ustrezno zdravniško oskrbo.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 09 September 2016 
Datum prve odobritve: 09. september 2016
The results from the Investigator determined analysis and IRC-determined analysis of PFS were consistent. 
Rezultati analize raziskovalcev in analize IRC so bili konsistentni.
• Dry mouth and pain in the mouth 
• suha usta in bolečina v ustih
You should tell your doctor about every medicine, but in particular if taking: 
Zdravniku morate povedati za vsako zdravilo, ki ga jemljete, še zlasti:
Cabozantinib treatment should be stopped at least 28 days prior to scheduled surgery, including dental surgery, if possible. 
Zdravljenje s kabozantinibom je treba ustaviti vsaj 28 dni pred načrtovanim kirurškim posegom, vključno z zobozdravstvenim, če je mogoče.
The clinical relevance of the observed neoplastic lesions in rats is uncertain, but likely to be low. 
Klinični pomen opaženih neoplastičnih sprememb pri podganah je negotov, a po vsej verjetnosti majhen.
Two dose reductions were required in 33% of patients. 
Dve zmanjšanji odmerka sta bili potrebni pri 33 % bolnikov.
The tablets should be swallowed whole and not crushed. 
Tablete je treba pogoltniti cele in jih ni dovoljeno drobiti.
CABOMETYX is not recommended for children or adolescents. 
Uporaba zdravila CABOMETYX se ne priporoča za otroke in mladostnike.
Complete responses (CR) Partial responses (PR) ORR (CR+PR)) p-value1,4 
Popolni odzivi (CR) Delni odzivi (PR) ORR (CR+PR) p-vrednost1,4
There is no information on the precise food-effect when taken 1 hour after administration of cabozantinib. 
Ni informacij o natančnem učinku hrane, če se uporabi 1 uro po dajanju kabozantiniba.
• Increase in the level of bilirubin in the blood (which may result in jaundice/yellow skin or eyes) 
• zvišanje ravni bilirubina v krvi (kar lahko povzroči zlatenico/rumeno obarvanje kože ali očesnih beločnic)
The carcinogenic potential of cabozantinib has been evaluated in two species: rasH2 transgenic mice and Sprague-Dawley rats. 
Kancerogeni potencial kabozantiniba so vrednotili pri dveh vrstah: rasH2 transgenih miših in podganah pasme Sprague-Dawley.
Keep in mind that treatment with CABOMETYX may make you feel tired or weak and can affect your ability to drive or use machines. 
Ne pozabite, da lahko zdravljenje z zdravilom CABOMETYX povzroči utrujenost ali šibkost, kar lahko vpliva na vašo sposobnost upravljanja vozil in strojev.
Approximately 75% of patients had a nephrectomy prior to onset of treatment. 
Pred začetkom zdravljenja je imelo približno 75 % bolnikov opravljeno nefrektomijo.
Patients should be monitored for signs and symptoms of hepatic encephalopathy. 
Bolnike je treba spremljati glede znakov in simptomov jetrne encefalopatije.
• A wound that does not heal. 
• rana, ki se ne celi
Number at risk: 
Število izpostavljenih tveganju:
Tumor assessments were conducted every 8 weeks for the first 12 months, then every 12 weeks thereafter. 
Vrednotenje tumorja so prvih 12 mesecev opravili vsakih 8 tednov, nato pa vsakih 12 tednov.
Tumor assessments were conducted every 12 weeks. 
Vrednotenje tumorja je bilo opravljeno vsakih 12 tednov.
Talk to your doctor about which methods of contraception are appropriate while you are taking CABOMETYX (see also under Other medicines and CABOMETYX, above). 
S svojim zdravnikom se posvetujte o metodah kontracepcije, ki so ustrezne med uporabo zdravila CABOMETYX (glejte tudi zgoraj pod Druga zdravila in zdravilo CABOMETYX).
If you get serious side effects, your doctor may decide to change your dose or stop treatment earlier than originally planned. 
Če dobite resne neželene učinke, bo morda zdravnik spremenil odmerek ali zdravljenje ustavil prej, kot je bilo načrtovano.
Non-disease specific quality of life (QoL) was assessed using the EuroQoL EQ-5D-5L. 
Ovrednotena je bila za bolezen nespecifična kakovost življenja s pomočjo vprašalnika EuroQoL EQ5D-5L.
• Gastro-oesophageal reflux disease (bringing up stomach acid) 
• gastroezofagealna refluksna bolezen (dvigovanje želodčne kisline)
This syndrome should be considered in any patient presenting with multiple symptoms, including seizures, headache, visual disturbances, confusion or altered mental function. 
Na ta sindrom je treba pomisliti pri vseh bolnikih s številnimi prisotnimi simptomi, vključno z epileptičnimi napadi, glavobolom, motnjami vida, zmedenostjo ali spremenjenim mentalnim delovanjem.
• Changes in blood tests used to monitor general health and function of your organs (including the liver, and kidney), low levels of electrolytes (like magnesium, or potassium) 
• spremembe krvnih preiskav, ki se uporabljajo za spremljanje splošnega zdravja in delovanja organov (vključno z jetri in ledvicami), nizke ravni elektrolitov (kot sta magnezij in kalij)
Because oral contraceptives might possibly not be considered as “effective methods of contraception”, they should be used together with another method, such as a barrier method (see section 4.5). 
Ker se morda peroralni kontraceptivi ne obravnavajo kot "zanesljiv način kontracepcije", jih je treba uporabiti skupaj s še eno metodo, na primer pregradno metodo (glejte poglavje 4.5).
Subjects with severe renal impairment have not been studied. 
Oseb s hudo okvaro ledvic niso preučevali.
Your doctor may also prescribe other medicines to help control your side effects. 
Zdravnik vam bo morda predpisal tudi druga zdravila za obvladovanje neželenih učinkov.
If you or your partner could become pregnant, use adequate contraception during treatment and for at least 4 months after treatment has finished. 
Če lahko vi ali vaša partnerica zanosite, morate med zdravljenjem in še vsaj 4 mesece po koncu zdravljenja uporabljati ustrezno kontracepcijo.
If you take CABOMETYX whilst using oral contraceptives, the oral contraceptives may be ineffective. 
Če jemljete zdravilo CABOMETYX med uporabo peroralnih kontraceptivov, so lahko peroralni kontraceptivi neučinkoviti.
• Anaemia (low levels of red blood cells) 
• anemija (nizka raven rdečih krvnih celic)
• A painful tear or abnormal connection of the tissues in your body 
• boleča raztrganina ali nenormalna spojitev tkiv v telesu
The safety and efficacy of cabozantinib in children and adolescents aged <18 years have not yet been established. 
Varnost in učinkovitost kabozantiniba pri otrocih, starih < 18 let, še nista bili dokazani.
The median time to first dose reduction was 55 days, and to first dose interruption was 38 days. 
Mediani čas do prvega zmanjšanja odmerka je bil 55 dni, do prve prekinitve odmerjanja pa 38 dni.
Treatment Modification 
Prilagajanje zdravljenja
RPLS is rare (it affects less than 1 in 1000 people). 
RPLS je redek neželeni učinek (pojavi se pri manj kot 1 od 1.000 bolnikov).
Patients could have received other prior therapies, including cytokines, and antibodies targeting VEGF, the programmed death 1 (PD-1) receptor, or its ligands. 
Bolniki so lahko pred tem prejemali druge oblike terapij, vključno s citokini in protitelesi, ki ciljajo VEGF, receptorje programirane smrti 1 (PD-1) ali njihove ligande.
Grade 2 adverse reactions which are intolerable and cannot be managed with a dose reduction or supportive care 
Neželeni učinki 2. stopnje, ki jih bolnik ne prenaša in jih ni mogoče obravnavati z zmanjšanjem odmerka ali podporno oskrbo
Your doctor will tell you if you need your dose adjusted. 
Vaš zdravnik vam bo povedal, ali je treba odmerek prilagoditi.
Objective response rate findings are summarized in Table 4. 
Izsledki stopnje objektivnega odziva so povzeti v preglednici 4.
It is not known whether cabozantinib and/or its metabolites are excreted in human milk. 
Ni znano, ali se kabozantinib in/ali njegovi presnovki izločajo v materino mleko.
Kaplan-Meier landmark estimates of percent of subjects event-free at 3 months % (95% CI) 
Kaplan-Meierjevi landmark oceni odstotka oseb brez dogodka v 3. mesecu % (95-% IZ)
These proteins can be present in high amounts in cancer cells, and by blocking their action CABOMETYX can slow down the rate at which the tumour grows and help to cut off the blood supply that the cancer needs. 
Te beljakovine so lahko v rakavih celicah prisotne v velikih količinah, zato lahko zdravilo CABOMETYX z zavrtjem njihove aktivnosti upočasni hitrost rasti tumorja in pomaga prekiniti oskrbo krvi, ki jo potrebuje rak.
Avoid consuming grapefruitcontaining products for as long as you are using this medicine, as they may increase the levels of CABOMETYX in your blood. 
Dokler uporabljate to zdravilo, ne jejte živil, ki vsebujejo grenivko, saj lahko zvišajo ravni zdravila CABOMETYX v krvi.
The median time to first dose reduction was 38 days, and to first dose interruption was 28 days. 
Mediani čas do prvega zmanjšanja odmerka je bil 38 dni, do prve prekinitve odmerjanja pa 28 dni.
Seventy-one percent (71%) received only one prior VEGFR TKI; 41% of patients received sunitinib as their only prior VEGFR TKI. 
Enainsedemdeset odstotkov (71 %) je pred tem prejelo le en VEGFR TKI; 41 % bolnikov je prejelo sunitinib kot edini prejšnji VEGFR TKI.
Women taking CABOMETYX should not breast-feed during treatment and for at least 4 months after treatment has finished, as cabozantinib and/or its metabolites may be excreted in breast milk and be harmful to your child. 
Ženske, ki jemljejo zdravilo CABOMETYX, med zdravljenjem in še vsaj 4 mesece po koncu zdravljenja ne smejo dojiti, saj se lahko kabozantinib in/ali njegovi presnovki izločajo v materino mleko in škodujejo otroku.
Primary Analysis ORR IntentTo-Treat Population (IRC) 
Primarna analiza ORR populacije z namenom zdravljenja (IRC)
No dose adjustment is necessary based on ethnicity (see section 5.2) 
Na osnovi etničnega porekla odmerka ni treba prilagajati (glejte poglavje 5.2).
Fifty-four percent (54%) of patients had 3 or more organs with metastatic disease, including lung (63%), lymph nodes (62%), liver (29%), and bone (22%). 
Štiriinpetdeset odstotkov (54 %) bolnikov je imelo 3 organe ali več z metastatsko boleznijo, vključno s pljuči (63 %), bezgavkami (62 %), jetri (29 %) in kostmi (22 %).
This is because CABOMETYX can affect the way some other medicines work. 
Zdravilo CABOMETYX lahko namreč vpliva na način delovanja nekaterih drugih zdravil.
• Severe or uncontrollable bleeding with symptoms such as: vomiting blood, black stolls, bloody urine, headache, coughing up blood. 
• resna ali nenadzorovana krvavitev s simptomi, kot so: bruhanje krvi, črno blato, krvav urin, glavobol, izkašljevanje krvi
Tell your doctor if you or your partner become pregnant or plan to become pregnant while you are being treated with CABOMETYX. 
Zdravniku povejte, če vi ali vaša partnerica zanosite ali načrtujete zanositev med zdravljenjem z zdravilom CABOMETYX.
Patients who have a history of severe bleeding prior to treatment initiation should be carefully evaluated before initiating cabozantinib therapy. 
Bolnike z anamnezo hude krvavitve pred uvedbo zdravljenja je treba pred uvedbo zdravljenja s kabozantinibom skrbno oceniti.
The median duration of treatment was 7.6 months (range 0.3 - 20.5) for patients receiving CABOMETYX and 4.4 months (range 0.21 - 18.9) for patients receiving everolimus. 
Mediano trajanje zdravljenja je bilo 7,6 meseca (razpon od 0,3 do 20,5) za bolnike, ki so dobivali zdravilo CABOMETYX, in 4,4 meseca (razpon od 0,21 do 18,9) za bolnike, ki so dobivali everolimus.
Diarrhoea, nausea/vomiting, decreased appetite, and stomatitis/oral pain were some of the most commonly reported GI adverse reactions (see section 4.8). 
Driska, navzea/bruhanje, zmanjšanje apetita in vnetje ustne sluznice/bolečina v ustni votlini so nekateri od najpogosteje poročanih neželenih učinkov na prebavila (glejte poglavje 4.8).
Subjects continued blinded study treatment after radiological disease progression whilst they experienced clinical benefit or until the need for subsequent systemic or liver directed local anticancer therapy. 
Osebe so nadaljevale slepo zdravljenje v študiji po radiološko potrjenem napredovanju bolezni, če je bila prisotna klinična korist ali do potrebe po naknadnem sistemskem ali v jetra usmerjenem lokalnem protitumorskem zdravljenju.
CABOMETYX (cabozantinib) tablets and COMETRIQ (cabozantinib) capsules are not bioequivalent and should not be used interchangeably (see section 5.2). 
Zdravili CABOMETYX (kabozantinib) tablete in COMETRIQ (kabozantinib) kapsule nista bioekvivalentni, zato se ju ne sme prosto zamenjevati (glejte poglavje 5.2).
In HCC patients with compromised livers, these non-hepatic effects may be precipitating factors for the development of hepatic encephalopathy. 
Pri bolnikih s HCK s kompromitiranimi jetri so ti ne-jetrni učinki lahko sprožilni dejavnik za razvoj jetrne encefalopatije.
Juvenile rats (correlating to a <2- year paediatric population) showed similar treatment-related findings but appeared to be more sensitive to cabozantinib-related toxicity at comparable dose levels. 
Ocenitve mladih podgan (primerljivo z < 2-letno pediatrično populacijo) so pokazale podobne izsledke za zdravljenje, vendar kaže, da je občutljivost za toksičnost zaradi kabozantiniba pri primerljivih ravneh odmerkov večja.
Cabozantinib was not carcinogenic in the rasH2 mouse model at a slightly higher exposure than the intended human therapeutic exposure. 
Kabozantinib v mišjem modelu rasH2 ni bil kancerogen pri nekoliko večji izpostavljenosti od nameravane terapevtske izpostavljenosti ljudi.
This may be due to liver problems. 
To bi lahko bile posledice težav z jetri.
Cabozantinib has minor influence on the ability to drive and use machines. 
Kabozantinib ima blag vpliv na sposobnost vožnje in upravljanja strojev.
Interrupt treatment until the adverse reaction resolves to Grade ≤1. 
Zdravljenje prekinite, dokler neželeni učinki ne izzvenijo do ≤ 1. stopnje.
Events were Grade 4 and 5. 
Dogodki so bili 4. in 5. stopnje.
The Kaplan- Meier estimates for median duration of OS were 11.1 months in the cabozantinib arm versus 6.9 months in the placebo arm, an estimated 4.2-month difference in the medians. 
Kaplan-Meierjevi oceni mediane trajanja celokupnega preživetja (OS) sta znašali 11,1 meseca v skupini s kabozantinibom v primerjavi s 6,9 meseca v skupini s placebom, z ocenjeno razliko mediane 4,2 meseca.
Objective Response Rate n (%)3 
Delež objektivnega odziva n (%)3
Prompt medical management, including supportive care with antiemetics, antidiarrhoeals, or antacids, should be instituted to prevent dehydration, electrolyte imbalances and weight loss. 
Nemudoma je treba uvesti ustrezne medicinske ukrepe, vključno s podpornim zdravljenjem z antiemetiki, antidiaroiki ali antacidi, da se prepreči dehidracija, neravnovesje elektrolitov in izguba telesne mase.
In vitro data demonstrate that cabozantinib is a substrate of MRP2. 
Podatki in vitro kažejo, da je kabozantinib substrat za MRP2.
PVC/PCTFE blister with push-through aluminum foil backing containing 7 film-coated tablets. 
Pretisni omot PVC/PCTFE z aluminijasto folijo, skozi katero se potisne tableta; vsebuje 7 filmsko obloženih tablet.
Progression-free survival (PFS) was assessed by a blinded independent radiology review committee, and the primary analysis was conducted among the first 375 subjects randomized. 
Preživetje brez napredovanja (PFS, progression-free survival) je slepo ocenila neodvisna radiološka komisija, primarno analizo pa so izvedli pri prvih 375 randomiziranih osebah.
No case of RPLS was reported in the METEOR or CABOSUN or CELESTIAL studies, but RPLS has been reported rarely in other clinical studies (in 2/4872 subjects; 0.04%). 
V študijah METEOR, CABOSUN ali CELESTIAL niso poročali o nobenem primeru RPLS, so pa o redkih primerih RPLS poročali v drugih kliničnih študijah (pri 2/4.872 oseb; 0,04 %).
Findings in uterus/ovaries and decreased haematopoiesis appeared to be transient, while effects on bone parameters and liver pigmentation were sustained. 
Kaže, da so izsledki v maternici/jajčnikih in zmanjšana hematopoeza prehodni, medtem ko so učinki na kostne parametre in pigmentacijo jeter trajni.
CABOMETYX tablets are available in packs containing either 4 blisters with 7 tablets each (28 total), or one plastic bottle with 30 tablets. 
Zdravilo CABOMETYX tablete je na voljo v pakiranjih, ki vsebujejo 4 pretisne omote po 7 tablet (skupaj 28) ali eno plastenko s 30 tabletami.
In the case of persistent hypertension despite use of anti-hypertensives, the cabozantinib dose should be reduced. 
V primeru trdovratne hipertenzije, kljub uporabi antihipertenzivov, je treba odmerek kabozantiniba zmanjšati.
Progressive Disease 
Napredujoča bolezen
If you have taken more CABOMETYX than you have been instructed to, talk to a doctor or go to the hospital with the tablets and this leaflet straight away. 
Če ste vzeli večji odmerek zdravila CABOMETYX, kot bi smeli Če ste vzeli več zdravila CABOMETYX, kot vam je bilo naročeno, se pogovorite z zdravnikom ali pojdite takoj v bolnišnico s tabletami in tem navodilom.
Injury, poisoning and procedural complications wound complications 
Poškodbe in zastrupitve in zapleti pri posegih zapleti z ranami
ORR per Investigator Review Intent-To-Treat Population 
ORR po oceni raziskovalca populacije z namenom zdravljenja
Patient distribution by IMDC risk groups was 81% intermediate (1-2 risk factors) and 19% poor (≥3 risk factors). 
Porazdelitev bolnikov glede na skupine tveganja po IMDC je bila 81 % za srednje ugoden (1-2 dejavnika tveganja) in 19 % za slab prognostični obet (≥ 3 dejavniki tveganja).
A less than 10% difference in the AUC was observed between cabozantinib tablet (CABOMETYX) and capsule (COMETRIQ) formulations. 
Manj kot 10-% razliko za AUC so opazili za tablete kabozantiniba (zdravilo CABOMETYX) in kapsule (zdravilo COMETRIQ).
What CABOMETYX is and what it is used for 
Kaj je zdravilo CABOMETYX in za kaj ga uporabljamo
If adverse reaction resolves to Grade ≤1, re-initiate at a reduced dose. 
Če neželeni učinki izzvenijo do ≤ 1. stopnje, ponovno uvedite zdravljenje z zmanjšanim odmerkom.
BATCH NUMBER<, DONATION AND PRODUCT CODES> 
ŠTEVILKA SERIJE<, ENOTNE OZNAKE DAROVANJA IN IZDELKOV> Lot
Most patients (87%) had ECOG performance status of 0 or 1; 13% had an ECOG performance status of 2. 
Večina bolnikov (87 %) je imela oceno stanja telesne zmogljivosti po lestvici ECOG 0 ali 1; 13 % bolnikov je imelo oceno stanja telesne zmogljivosti po lestvici ECOG 2.
The study was not powered for the OS analysis and the data are immature. 
Študija ni imela moči za analizo celokupnega preživetja, podatki pa niso bili zreli.
Pharmacotherapeutic group: antineoplastic agent, protein kinase inhibitor, ATC code: L01XE26. 
Farmakoterapevtska skupina: zdravila z delovanjem na novotvorbe (citostatiki), zaviralci proteinske kinaze, oznaka ATC: L01XE26
• Blood clots in the veins, arteries and lungs 
• krvni strdki v venah, arterijah in pljučih
In addition, cabozantinib inhibits other tyrosine kinases including the GAS6 receptor (AXL), RET, ROS1, TYRO3, MER, the stem cell factor receptor (KIT), TRKB, Fms-like tyrosine kinase-3 (FLT3), and TIE-2. 
Poleg tega kabozantinib zavira druge tirozin-kinaze, vključno z receptorjem GAS6 (AXL), RET, ROS1, TYRO3, MER, receptorjem faktorja matičnih celic (KIT), TRKB, Fms-ju podobno tirozin-kinazo-3 (FLT3) in TIE-2.
Therefore, caution should be recommended when driving or operating machines. 
Zato je potrebna pri vožnji ali upravljanju strojev previdnost.
Patients were stratified by IMDC risk group and presence of bone metastases (yes/no). 
Bolniki so bili stratificirani glede na skupino tveganja po IMDC in glede na prisotnost zasevkov v kosteh (da/ne).
CABOMETYX treatment was associated with a trend for longer survival compared to sunitinib (Table 5). 
Zdravljenje z zdravilom CABOMETYX je bilo povezano s trendom k daljšemu preživetju v primerjavi z zdravljenjem s sunitinibom (preglednica 5).
The CELESTIAL study excluded patients with concomitant anticoagulation treatment or antiplatelet agents. 
Iz študije CELESTIAL so bili izključeni bolniki, ki so se sočasno zdravili z antikoagulanti ali antitrombotičnimi zdravili.
Cabozantinib should be used with caution in patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. 
Kabozantinib je treba uporabljati previdno pri bolnikih s podaljšanjem intervala QT v anamnezi, pri bolnikih, ki jemljejo antiaritmike, in pri bolnikih z relevantno obstoječo boleznijo srca, bradikardijo ali elektrolitskimi motnjami.
Adverse reactions are listed in Table 2 according to MedDRA System Organ Class and frequency categories. 
Neželeni učinki v preglednici 2 so razvrščeni po dogovoru MedDRA po organskih sistemih in pogostnosti.
Patients with treated brain metastases were allowed. 
Bolniki z zdravljenimi metastazami v možganih so bili vključeni.